Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 14/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL7047847 | 0.86 | GPR84 (0.43) | GPR84 | |
| Choline SCHEMBL1938782 | 0.83 | POLB (0.42) | GPR84 | |
| Phosphoric Acid SCHEMBL1231445 | 0.80 | GPR84 (0.54) | TDO2GPR84HTR2AHTR1A | |
| Choline SCHEMBL7047866 | 0.79 | NR4A2 (0.40) | GPR84HTR2A | |
| Choline SCHEMBL7041896 | 0.77 | CSNK2A1 (0.38) | — | |
| SCHEMBL1931747 | 0.76 | GPR84 (0.63) | TDO2GPR84HTR2AHTR1A | |
| Choline SCHEMBL7044734 | 0.72 | CYP3A4 (0.44) | GPR84HTR2AHTR1A | |
| Choline SCHEMBL7041289 | 0.71 | GPR84 (0.40) | GPR84HTR2AHTR1A | |
| Choline SCHEMBL1938812 | 0.71 | — | — | |
| Choline SCHEMBL136984 | 0.67 | LMNA (0.60) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660494-B2 | Detecting phosphatidylcholine-specific phospholipase-C enzyme via incorporation of 3-indoxyl choline phosphate into substrate | BIOSYNTH AG (CH) | 2003-12-09 | — | — | US | disclosed |
| EP-1219628-B1 | Novel substrates for detection of microbial metabolites | BIOSYNTH AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020151725-A1 | Detection of microbial metabolites | BIOYNTH AG (CH) | 2002-10-17 | — | — | US | disclosed |
| WO-2002051853-A1 | DETECTION OF MICROBIAL METABOLITES | BIOSYNTH AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| EP-1219628-A1 | Novel substrates for detection of microbial metabolites | Biosynth AG (CH) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151725-A1 | Detection of microbial metabolites | LCT, CEL, PLCB1 | TDO2 352/4885GPR84 2820/4885HTR2A 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.